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Summary
Phagocytosing macrophages are involved in the induction of humoral immunity to corpuscular 
antigens. Recently, we demonstrated that B cell response to haptenated sheep red blood cells (SRBC) 
could be suppressed by extracellular vesicles (EVs) produced by suppressor T cells activated through 
intravenous administration of a high dose of syngeneic mouse red blood cells (sMRBC). However, 
the mechanism underlying the inhibitory effect of sMRBC-induced EVs on macrophages involved in 
activation of humoral immunity remained unclear. Thus, the current studies aimed at investigating 
the phagocytic and antigen-presenting activity of macrophages treated with sMRBC-induced EVs.
Mouse thioglycollate-induced peritoneal macrophages were treated with sMRBC-induced EVs 
and then pulsed with either native or fluorescein isothiocyanate-conjugated SRBC. Afterwards, 
macrophages were, respectively, administered intraperitoneally into naive recipients or sub-
jected to flow cytometric analysis. The elicited humoral immune response was evaluated in 
plaque forming and haemagglutination assays.
Decreased number of B cells secreting SRBC-specific antibodies was shown in spleens of mouse 
recipients of SRBC-pulsed macrophages pretreated with sMRBC-induced EVs along with an 
increased ratio of IgM to IgG serum antibodies. Furthermore, pretreatment of macrophages 
with sMRBC-induced EVs reduced their phagocytic activity and expression of costimulatory 
molecules involved in antigen phagocytosis and presentation.
Current research findings demonstrated the impaired ability of macrophages to activate B cells 
due to the action of sMRBC-induced EVs, which may play a role in suppressing self-reactive B cells. 
Thus, our results seem to have translational potential in development of therapeutic strategies to 
prevent the macrophage-induced humoral immunity against nonpathogenic antigens.
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ingly, a similar inhibitory effect was observed in the case 
of macrophages pretreated with extracellular vesicles 
(EVs) released by Ts cells activated through intravenous 
injection of a high dose of sMRBC alone [25]. However, the 
mechanism underlying the inhibitory effect of sMRBC-
-induced EVs on macrophages involved in the activation 
of humoral immunity remained unclear. Thus, we have 
undertaken the current studies to investigate the phago-
cytic and antigen-presenting activity of macrophages 
treated with sMRBC-induced EVs prior to pulsing with 
SRBC to induce B cell response.
MATERIALS AND METHODS
Mice
Ten to twelve week-old CBA mice from the Breeding Unit 
of Faculty of Medicine of the Jagiellonian University Med-
ical College (Krakow, Poland) were standardly fed with 
autoclaved food and water. All experiments were con-
ducted according to the guidelines of Jagiellonian Uni-
versity and Local Ethics Committee (approvals No 39/2011 
and 154/2013). Each experiment was repeated at least 
twice, and the representative results are shown in the 
figures, and, additionally, the general scheme of experi-
ments is depicted in Fig. 1.
Generation of sMRBC-induced EVs
Freshly collected and deprived of buffy coat syngeneic 
mouse red blood cells (sMRBC) were intravenously injected 
in 0.2ml of 10% DPBS suspension on days 0 and 4 into naive 
mice. On day 11 spleens and lymph nodes of tolerized mice, 
containing activated Ts cells, were collected and single cell 
suspensions were cultured in protein-free Mishell-Dut-
ton medium at a concentration of 2×107 cells per ml for 48 
hours [4, 5, 25]. The resulting supernatant was then centri-
fuged at 300g and 3,000g for 10 minutes, filtered through 
0.45 µm and 0.22 µm molecular filters, which was followed 
by double ultracentrifugation at 100,000g for 70 minutes at 
4ºC [4, 25]. Obtained pellet was resuspended in DPBS and 
used as sMRBC-induced EVs [4, 25].
INTRODUCTION
Due to their ability to phagocytose and intracellularly 
process antigen to finally present its determinants com-
plexed with major histocompatibility (MHC) class II mol-
ecules, macrophages are considered as cells cross linking 
innate and adaptive immunity. Depending on the type of 
activating stimuli, macrophages can be classified as clas-
sically activated M1 pro-inflammatory phenotype or 
altern atively activated M2 anti-inflammatory phenotype. 
However, due to the high plasticity of phenotype switching 
regulated by current tissue conditions, macrophages usu-
ally express the intermediary activation status [21]. Inter-
estingly, recent studies revealed that phagocytic activity of 
macrophages not only results from but also imprints the 
heterogeneity of tissue-resident macrophage populations, 
expressing a great impact on cellular homeostasis of the 
organism [1]. Consequently, phagocytosing macrophages 
contribute to both anti-microbial responses activating 
host immune defense and clearance of cellular debris, 
allowing immunization to self-cells to be avoided [21]. 
However, still little is known about phagocytic functions 
of macrophages involved in the activation of immune tol-
erance to non-self-antigens.
Our current research findings in mouse model of con-
tact (CHS) and delayed-type hypersensitivity (DTH) 
reactions [4, 5, 22, 26] demonstrated the crucial role of 
macrophages in the activation of immune tolerance by 
CD8pos suppressor T (Ts) cells  [25], activated through 
intravenous administration of a high dose of syngeneic 
mouse red blood cells (sMRBC) conjugated with  hapten 
or protein antigen  [4]. These cells then release reg-
ulatory exosomes carrying miRNA-150 and further coated 
with antibody light chains [20], enabling the delivery of 
exosomes to antigen-presenting cells [22]. This finally 
results in antigen-specific suppression of CHS and DTH 
reactions in mice [4, 5, 20, 22, 25, 26]. Antigen-presenting 
macrophages altered with miRNA-150-carrying exosomes, 
when pulsed with hapten-conjugated sheep red blood 
cells (SRBC), expressed impaired ability to induce anti-
gen-specific antibody production by B cells [25]. Surpris-
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into naive mice. A week later blood sera and spleens 
of EV-pretreated, SRBC-pulsed macrophage recipients 
were individually collected.
Single cell suspensions of each spleen in RPMI1640 were 
incubated with 20% SRBC in the presence of guinea pig 
complement (Biomed, Lublin, Poland) for 90 minutes at 
37°C. Then, the number of hemolytic plaque forming 
cells (PFC) formed in a PFA performed by a slide tech-
nique was enumerated for each spleen in triplicates 
[8, 10, 23, 25]. The averaged results were then expressed 
as the number of PFC per spleen.
Titers of anti-SRBC antibodies (IgM and IgG) in whole 
sera along with titers of IgG antibodies in sera pre-
incub ated with 0.15 M 2-mercaptoethanol (Sigma, St. 
Louis, MO, USA) to eliminate IgM activity were meas-
ured in direct HA, as described previously [10, 23, 25]. 
The results were expressed as a log2 of titers. Titers of 
SRBC -specific IgM antibodies were estimated by sub-
traction of IgG titers from total antibody titers.
The data was analyzed with GraphPad Prism and Excel 
software with the assessment of statistical significance 
of differences between groups in two-tailed Student’s 
T test, and p<0.05 was considered statistically significant.
Macrophage harvest
Peritoneal exudate macrophages were induced 
by intraperitoneal injection of 2 ml of thioglycol-
late medium (Gibco Life Technologies, Grand Island, 
NY) [10] and harvested 5 days later by washing the 
peritoneal cavity with ice-cold DPBS containing hep-
arin (5U/ml, Polfa, Warszawa, Poland). Then, the per-
centage of macrophages in isolated exudates was 
evaluated with non-specific esterase assay [7] and in 
each case exceeded 96%.
Plaque Forming (PFA) and Haemagglutination 
(HA) Assays 
Macrophages were treated or not in vitro with sMRBC-
-induced EVs resuspended in DPBS in a dose of around 
4×109EVs (as estimated by Nanoparticle Tracking Anal-
ysis [4]) per 1×106 cells for 30 minutes in 37°C water-
bath. Then, macrophages were pulsed with sheep red 
blood cells (SRBC, Graso Biotech, Starogard Gdanski, 
Poland) by incubation for additional 30 minutes at 37°C 
in a ratio of 10 SRBC per single macrophage. This was 
followed by the removal of non-phagocytosed SRBC by 
osmotic shock. Finally, SRBC-pulsed macrophages were 
injected intraperitoneally (4×106 cells per recipient) 
Fig. 1. The general scheme of experiments. EVs – extracellular vesicles; FITC-SRBC – fluorescein isothiocyanate-conjugated sheep red blood cells; HA  
– haemagglutination assay; PFA – plaque forming assay; sMRBC – syngeneic mouse red blood cells; SRBC – sheep red blood cells.
639
Nazimek K. et al. – Extracellular vesicles induced...
The acquired data were analyzed with BD CellQuest Pro, 
GraphPad Prism 8 and Excel software. The remaining 
FITC-SRBC-pulsed macrophages, after osmotic shock, 
were incubated for additional 120 minutes in 37°C water-
bath to allow for eventual antigen processing. Then, the 
efficacy of phagocytosis was similarly analyzed by flow 
cytometry after staining with APC-conjugated anti-
mouse F4/80 monoclonal antibody and addition of 7-AAD 
viability dye. The gating strategy and representat ive 
results are shown in Fig. 2.
Assessment of macrophage surface markers’ 
expression
Macrophages incubated or not with sMRBC-induced 
EVs were pulsed with FITC-SRBC as described above and, 
after osmotic shock, were incubated for additional 120 
minutes in 37°C water-bath to stimulate the processing 
Phagocytosis assay
Macrophages were treated in vitro with sMRBC-induced 
EVs as above. Phagocytosis assay was then performed, as 
recently described by us [9]. Briefly, SRBC, after labelling 
with fluorescein isothiocyanate (FITC, Sigma, St. Louis, 
MO, USA), were added to macrophages in a ratio of 10 
FITC-SRBC per single macrophage. Cells were incubated 
for 20 minutes at 37ºC, which was followed by removal 
of non-phagocytosed FITC-SRBC by osmotic shock. To 
assess the efficacy of FITC-SRBC phagocytosis by EV-pre-
treated macrophages, part of the cells, after addition of 
viability dye, namely 7-amino-actinomycin D (7-AAD, BD 
Biosciences, San Diego, CA, USA), was stained with allo-
phycocyanin (APC)-conjugated anti-mouse F4/80 mon-
oclonal antibody (eBioscience Inc., San Diego, CA, USA) 
and then immediately subjected to flow cytometry anal-
ysis on FACS Calibur (BD Biosciences, San Jose, CA, USA). 
Fig. 2. The gating strategy and representative results of cytometric analysis. EV – extracellular vesicle; MFI – geometric mean of fluorescence intensity; min  
– minutes; pos – positive; R1, R2 – gate numbers; UR – upper right. 
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bility after phagocytosis of FITC-SRBC showed no differ-
ences between untreated and EV-treated macrophages 
(Fig. 4A). However, the significantly decreased percentage 
of viable macrophages that phagocytosed FITC-SRBC was 
demonstrated in the case of cells pretreated with sMRBC-
-induced EVs, both when assessed immediately or 2 hours 
after incubation with antigen (Fig. 4B). Furthermore, after 
treatment of peritoneal exudate cells with sMRBC-induced 
EVs, the increased percentage of F4/80pos macrophages was 
detected (Fig. 5A) along with the slightly enhanced expres-
sion of this marker on EV-treated macrophages (Fig. 5B). 
Finally, treatment with sMRBC-induced EVs resulted in 
significantly reduced percentage of F4/80pos macrophages 
that phagocytosed FITC-SRBC (Fig. 5C). These findings con-
firmed that sMRBC-induced EVs alter the phagocytic activ-
ity of mouse peritoneal macrophages.
sMRBC-induced EVs influence macrophage 
activation status
We assumed that alteration of antigen phagocytosis by 
F4/80pos macrophages [28] can further affect its processing 
and eventual presentation. To test this hypothesis, we have 
stained EV-pretreated and FITC-SRBC-pulsed macrophages 
with fluorochrome-conjugated antibodies against surface 
and eventual presentation of antigen. Afterwards, cells 
were stained with APC-conjugated anti-mouse F4/80 mon-
oclonal antibody and with phycoerythrin (PE)-conjugated 
monoclonal antibodies against one of the following mouse 
markers: I-Ak, CD80, CD86, CD40, CD11b, Mac-3 from (BD 
Biosciences, San Diego, CA, USA), and CD68 or CD206 from 
(eBioscience Inc., San Diego, CA, USA). Just before cytomet-
ric analysis on FACS Calibur (BD Biosciences, San Jose, CA, 
USA), propidium iodide (PI, BD Pharmingen, San Diego, 
CA, USA) was added to each  sample. The acquired data 
was then initially analyzed with BD CellQuest Pro software 
and statistically analyzed as above with GraphPad Prism 5 
and Excel software. The gating strategy and representative 
results are shown in Fig. 2.
RESULTS
Activation of B cell response by macrophages is 
impaired under the influence of sMRBC-induced EVs
Our prior studies revealed that both hapten-specific, 
miRNA-150-carrying exosomes and sMRBC-induced EVs 
reduce macrophage ability to induce humoral immune 
response to hapten-conjugated SRBC [25]. However, it has 
remained unclear whether the suppressive action of EVs 
on macrophages involved in the activation of B cells could 
be achieved either due to hapten binding to SRBC or is 
a general phenomenon, and thus can be observed in the 
case of humoral immunity to native antigen. To solve these 
doubts, we have pretreated macrophages with sMRBC-
-induced EVs prior to pulsing with native SRBC and then 
transferred them into naive recipients, which was fol-
lowed by assessment of humoral immune response activa-
tion a week later. Consequently, we found the signi ficantly 
decreased number of B cells releasing SRBC-specific 
antibodies in spleens of recipients of macrophages pre-
treated with sMRBC-induced EVs (Fig. 3A). Furthermore, 
we detected an increased ratio of SRBC-specific IgM to 
IgG antibodies in sera of mice administered with EVs-pre-
treated macrophages (Fig. 3B). These results demonstrated 
that sMRBC-induced EVs impair macrophage ability to 
activ ate antigen-specific B cells and their maturation. Thus, 
our data confirms that miRNA-150-carrying EVs impact 
macrophage functions not only in cell-mediated immune 
response [25], but also in a humoral immunity.
sMRBC-induced EVs affect macrophage phagocytic 
activity
The above results showed that sMRBC-induced EVs impair 
macrophage-mediated activation of B cells. However, the 
mechanism underlying this phenomenon has been yet 
undefined. We assumed that the impairment of humoral 
immunity may result from the reduction of antigen phago-
cytosis or presentation by macrophages, or from altered 
interaction of macrophages with B cells and T helper lym-
phocytes. To test these assumptions, we had incubated 
EV-pretreated macrophages with FITC-coupled SRBC, 
and then cytometrically analyzed cell viability and the 
efficacy of phagocytosis. Assessment of macrophage via-
Fig. 3. Assessment of humoral immune response induced by macrophages 
pretreated with extracellular vesicles induced by syngeneic mouse red blood 
cell (sMRBC) injection prior to pulsing with sheep red blood cells (SRBC) 
evaluated as (A) the number of hemolytic plaque forming B cells in spleens 
and (B) specific antibody titers in blood sera of mouse macrophage recipients. 
Graphs depict mean ± standard deviation (SD).
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ing CD11b and CD68 markers among F4/80pos popula-
tion, the increased percentage of cells expressing Mac3 
marker and decreased percentage of cells displaying 
CD206 receptor was found in the case of F4/80pos mac-
rophages pretreated with sMRBC-induced EVs, with 
markers of macrophage activation and antigen presenta-
tion. Accordingly, we have found no significant differences 
in expression of MHC class II and CD40 molecules between 
untreated and EV-pretreated F4/80posF4/80pos macrophages. 
However, we have observed the decreased percentage of 
F4/80posCD80pos cells among EV-pretreated macrophages 
along with lower intensity of PE fluorescence emitted by 
these cells and F4/80posCD86pos macrophages (Table 1). 
These observations suggest that treatment of macrophages 
with sMRBC-induced EVs slightly influences the expression 
of costimulatory molecules.
Further, we have analyzed the expression of mol-
ecules recognized as markers of macrophage phe-
notype and activation status, including CD206, i.e. 
mannose re ceptor, characteristic for M2 polarized mac-
rophages [21], and Mac3 considered as a marker of activ-
ated macrophages [10, 14]. While cytometric analysis 
demonstrated the similar percentage of cells express-
Fig. 4. Assessment of (A) viability and (B) phagocytic activity of peritoneal 
macrophages pretreated with extracellular vesicles (EVs) induced by syngeneic 
mouse red blood cell injection prior to pulsing with fluorescein isothiocyanate-
conjugated sheep red blood cells (FITC-SRBC), expressed as the percentage of cells 
not stained with 7-AAD viability dye and expressing FITC fluorescence, respectively. 
Graphs depict mean ± standard deviation (SD), *p <0.05; **p <0.01.
Fig. 5. Assessment of (A) viability, (B) intensity of F4/80 marker expression 
and (C) phagocytic activity of F4/80pos peritoneal macrophages pretreated with 
extracellular vesicles (EVs) induced by syngeneic mouse red blood cell injection 
prior to pulsing with fluorescein isothiocyanate-conjugated sheep red blood 
cells (FITC-SRBC), expressed as the percentage of F4/80pos cells not stained with 
7-AAD viability dye, as geometric mean of fluorescence intensity (MFI) and the 
percentage of F4/80pos cells expressing FITC fluorescence, respectively. Graphs 
depict mean ± standard deviation (SD), *p <0.05; ***p <0.005.
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conjugation with SRBC  [25]. Thus, we selected FITC-
-coupled SRBC to test macrophage phagocytic activity, 
which showed the decreased percentage of peritoneal 
exudate macrophages that phagocytosed FITC-SRBC 
when pretreated with sMRBC-induced EVs (Fig. 4). This 
result was especially clearly seen in the case of F4/80pos 
macrophages that tended to slightly dominate the pop-
ulation of viable peritoneal cells after treatment with 
sMRBC-induced EVs (Fig. 5). However, the difference 
in the percentage of F4/80pos macrophages that phago-
cytosed FITC-SRBC between untreated and EV-treated 
cells was less pronounced after 2-hour incubation. This 
may result from lower cell death ratio in the case of 
EV-pretreated F4/80pos macrophages (Fig. 5A). On the 
other hand, some of the F4/80pos macrophages pulsed 
with sMRBC-induced EVs and then with antigen seem to 
be characterized by an intermediary pattern of activa-
tion associated with an increased Mac3 and decreased 
CD206 markers’ expression along with reduced expres-
sion of costimulatory molecules (Table 1). It was pre-
viously suggested that CD80 and CD86 costimulatory 
molecules could overlap each other’s function during 
immunoglobulin class switch towards IgG in a response 
to antigen administered with an adjuvant [3]. In addi-
tion, CD86 may additionally costimulate the activation 
of Th1 cells in the case of emulsified antigens [2]. This 
seems to be in line with our observations that a slight 
decrease in CD80 and CD86 caused by sMRBC-induced 
EVs may impair the production of IgG in a response to 
haptenated antigens. Besides, elevated Mac3 expression, 
in some circumstances observed in classically activated 
macrophages [11], accompanied with lower expression 
of CD206 considered as a marker of an alternative mac-
rophage activation [21] suggests that some of the anti-
gen-primed F4/80pos macrophages underwent cytotoxic 
activation after pretreatment with sMRBC-induced EVs. 
This is in line with a formerly observed enhancement of 
generation of ROIs by peritoneal macrophages harvested 
from mice intravenously administered with a high dose 
of sMRBC [24] as another pattern of cytotoxic activa-
tion, which may be directed against effector T cells [27]. 
corresponding changes in fluorescence intensity (Table 
1). Taking into account the similar expression of MHC 
class II, but lower expression of CD80, one can assume 
that some of the antigen-primed macrophages influ-
enced with sMRBC-induced EVs seem to undergo the 
cytotoxic activation, which is in line with the previously 
reported enhancement of generation of reactive oxygen 
intermediates (ROIs) by mouse macrophages treated 
with miRNA-150-carrying EVs induced by intravenous 
administration of haptenated sMRBC [24].
DISCUSSION
Our previous reports implied that mere intravenous 
administration of a high dose of sMRBC may induce the 
generation of immune suppressive EVs that target anti-
gen-primed macrophages to eventually down-regulate 
humoral response against haptenated SRBC [25]. How-
ever, the mechanism underlying the observed effect 
remained unknown. Current research findings revealed 
that macrophages pretreated with sMRBC-induced EVs 
express the reduced ability to activate B cell response 
against native SRBC (Fig. 3) to a similar extent as in the 
case of haptenated SRBC [25]. Furthermore, an increased 
ratio of SRBC-specific IgM to IgG antibodies was also 
observed, suggesting the impairment of immuno globulin 
class switching during maturation of antigen-specific B 
cells. These observations suggest that targeting of mac-
rophages with sMRBC-induced EVs prior to pulsing with 
an antigen generally affects macrophage ability to acti-
vate antigen-specific B cells. sMRBC-induced EVs are 
suspected to contain immune regulatory miRNA-150 
(Nazimek et al., manuscript in preparation) [25], which 
was formerly shown to down-regulate B lymphocyte 
maturation [29, 31] and inflammatory functions [30]. 
However, the effects of miRNA-150 carried in sMRBC-
-induced EVs on phagocytic macrophages involved 
in induction of B cell function have not yet been elu-
cidated. Apart from ability to emit fluorescence after 
excitation, FITC molecules express haptenic proper-
ties [6], similarly to trinitrophenol previously used for 
Table 1. Expression of surface markers of antigen phagocytosis and presentation, and cell activation by macrophages treated with sMRBC-induced EVs.
marker 
(bound by PE-conjugated monoclonal 
antibodies)
F4/80pos mouse macrophages
untreated (control)
treated with 
sMRBC-induced EVs
% of positive cells geomean of PE fluorescence % of positive cells geomean of PE fluorescence
CD11b 97.3 ± 0.00 453.8 ± 0.00 97.1 ± 0.35 462.2 ± 47.3
Mac3 34.6 ± 0.92 159.8 ± 8.6 41.2 ± 2.76 187.5 ± 20.7
I-Ak (MHC II) 26.7 ± 2.33 232.1 ± 21.40 28.1 ± 0.21 230.5 ± 5.30
CD80 64.4 ± 3.25 106.1 ± 5.80 58.3 ± 1.48 98.5 ± 0.99
CD86 78.4 ± 0.78 149.9 ± 3.39 77.6 ± 1.77 142.8 ± 2.76
CD40 10.5 ± 1.63 70.8 ± 1.70 12.5 ± 0.42 71.9 ± 0.85
CD68 92.8 ± 1.48 220.7 ± 25.74 92.7 ± 0.35 223.9 ± 4.03
CD206 50.9 ± 0.92 146.2 ± 1.41 46.2 ± 0.28 137.1 ± 1.91
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molecule, considered as a main marker of tissue mac-
rophages  [28], formerly was suggested to enable the 
macrophage-mediated activation of CD8+ regulatory T 
lymphocytes [17]. In addition, macrophages were pro-
posed to induce regulatory T cells through generation 
of ROIs [16]. Thus, it could be assumed that regulatory T 
cells may also contribute to the suppression of humoral 
immunity by macrophages pretreated with sMRBC 
-induced EVs.
CONCLUSION
Our current research findings demonstrated subtle dif-
ferences in macrophage activation status caused by pre-
treatment with sMRBC-induced EVs prior to pulsing 
with haptenated SRBC. The resulting reduced phagocytic 
activity and expression of costimulatory molecules likely 
accompanied by cytotoxic activation, together seem to 
contribute to impaired ability of macrophages to activate 
B cells in humoral immune response. Simultaneously, 
other mechanisms, including EV-mediated intracellu-
lar signaling, could preserve this suppressive effect. Fur-
thermore, such an inhibitory effect of sMRBC-induced 
EVs may play a role in suppressing of self-reactive B cells. 
Altogether, the impact of sMRBC-induced EVs on mac-
rophage phagocytic and antigen-presenting activity in 
humoral immune response seems to have an important 
translational potential in the development of therapeutic 
strategies to prevent the macrophage-induced humoral 
immunity against nonpathogenic and self-antigens.
Although the direct macrophage cytotoxic action on 
B cells remains a matter of speculation, extracellularly-
derived ROIs were suggested to induce the B cell apop-
tosis, which could be reversed by IL-6 [19]. Interestingly, 
mice lacking the ability to generate ROIs were shown to 
be more prone to develop autoimmune responses with 
enhanced IgG and Th1 cell-mediated responses against 
self-antigen [15]. This observation brings another piece 
of evidence for the ability of cytotoxically-activated 
macrophages to down-regulate humoral immunity. 
Interestingly, miRNA-150 was also suggested to up-reg-
ulate the cellular oxidation process, which led to cell 
senescence [18]. Nonetheless, the involvement of other 
macrophage-derive secretory factors, like cytokines 
and EVs especially [13], cannot be excluded. It is worth 
noting that macrophages treated with miRNA-150-car-
rying EVs induced in mice by intravenous administra-
tion of haptenated sMRBC were suggested to release 
their own EVs that in turn suppress Th1 lympho-
cytes  [22]. Thus, a similar EV-mediated mechanism 
could also be responsible for the suppression of B cell 
response observed under the influence of macrophages 
treated with sMRBC-induced EVs. 
Phenotypic analysis of cells subjected to current assays 
revealed that they resemble the population of infiltrating 
macrophages, characteristic for thioglycollate-induced 
peritoneal exudate [12]. Furthermore, our results imply 
that sMRBC-induced EVs to some extent may enhance 
the persistence of F4/80pos macrophages (Fig. 5A). F4/80 
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